16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Identification of the cell-intrinsic and extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Many cancer types, including head and neck cancers (HNC), express programmed death ligand 1 (PD-L1). Interaction between PD-L1 and its receptor, programmed death 1 (PD-1), inhibits the function of activated T cells and results in an immunosuppressive microenvironment, but the stimuli that induce PD-L1 expression are not well characterized. Interferon gamma (IFNγ) and the epidermal growth factor receptor (EGFR) utilize Janus kinase 2 (JAK2) as a common signaling node to transmit tumor cell-mediated extrinsic or intrinsic signals, respectively. In this study, we investigated the mechanism by which these factors upregulate PD-L1 expression in HNC cells in the context of JAK/STAT pathway activation, Th1 inflammation, and HPV status. We found that wild type, overexpressed EGFR significantly correlated with JAK2 and PD-L1 expression in a large cohort of HNC specimens. Furthermore, PD-L1 expression was induced in an EGFR- and JAK2/STAT1-dependent manner, and specific JAK2 inhibition prevented PD-L1 upregulation in tumor cells and enhanced their immunogenicity. Collectively, our findings suggest a novel role for JAK2/STAT1 in EGFR-mediated immune evasion, and therapies targeting this signaling axis may be beneficial to block PD-L1 upregulation found in a large subset of HNC tumors.

          Related collections

          Author and article information

          Journal
          2984705R
          2786
          Cancer Res
          Cancer Res.
          Cancer research
          0008-5472
          1538-7445
          18 December 2015
          16 December 2015
          1 March 2016
          01 March 2017
          : 76
          : 5
          : 1031-1043
          Affiliations
          [1 ]Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA
          [2 ]Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA
          [3 ]Department of Periodontics and Oral Medicine, School of Dentistry and Department of Otolaryngology-Head and Neck Surgery, School of Medicine. University of Michigan, Ann Arbor, MI, USA
          [4 ]Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA
          [5 ]Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
          [6 ]Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA
          [7 ]Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
          Author notes
          Corresponding Author: Robert L. Ferris, MD, PhD, Hillman Cancer Center Research Pavilion, 5117 Centre Avenue, Room 2.26b, Pittsburgh, PA 15213-1863, Phone:412-623-0327, Fax:412-623-4840 ferrisrl@ 123456upmc.edu
          Article
          PMC4775348 PMC4775348 4775348 nihpa745548
          10.1158/0008-5472.CAN-15-2001
          4775348
          26676749
          620f4c4c-c6b3-45fb-89aa-b7b637db36df
          History
          Categories
          Article

          HPV,STAT1,EGFR,JAK2,PD-L1
          HPV, STAT1, EGFR, JAK2, PD-L1

          Comments

          Comment on this article